Amy V Morrow, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 407 W 66th St, Richfield, MN 55423 Phone: 612-798-8800 |
Anne Valaas-turner, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 407 W 66th St, Richfield, MN 55423 Phone: 612-798-8800 |
News Archive
Naviscan, Inc., the leader in Molecular Breast Imaging (MBI), today announced that Paul J. Mirabella, President and Chief Executive Officer, will be presenting a corporate update at the 4th Annual BIOCOM Investor Conference on October 27, 2009 at 1:00 p.m. being held at Hyatt Regency in La Jolla, California.
OncoGenex Pharmaceuticals, Inc. announced today the initiation of a Phase 3 registration trial of custirsen sodium (OGX-011/TV-1011), its lead product candidate being developed for the treatment of castrate-resistant prostate cancer (CRPC). This trial, referred to as the Prostate Cancer SATURN Trial, is the first of three Phase 3 trials to be initiated under a global collaboration and license agreement between OncoGenex and Teva Pharmaceutical Industries to develop and commercialize OGX-011/ TV-1011.
The Norwegian pharmaceutical company Lytix Biopharma AS today announced approvals from the Norwegian Medicines Agency ("Statens legemiddelverk") and the Swedish Medical Products Agency ("Läkemedelverket") to commence Phase I clinical trials of OncoporeTM (LTX-315) for the treatment of cancer.
Scientists from Nanyang Technological University, Singapore and the Korea Advanced Institute of Science & Technology have identified a new mechanism that causes the hallmark symptoms of Parkinson's disease, namely tremors, rigidity, and loss of voluntary movement.
A team including the scientist who first harnessed the revolutionary CRISPR-Cas9 system for mammalian genome editing has now identified a different CRISPR system with the potential for even simpler and more precise genome engineering.
› Verified 8 days ago